Statement 17 Mar 2023

WHO Intergovernmental Negotiating Body (INB) intersessional briefing on the “Predictable global supply chain and logistics network”

On 17 March, IFPMA delivered a shortened version of the below statement at the WHO INB intersessional briefing on “Article 6: Predictable global supply chain and logistics network” of the WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response (“WHO CA+”).

Statement 17 Mar 2023

Statement at the Human Rights Council 52 Regular Session: Interactive dialogue on access to COVID-19 vaccines

On 17 March, IFPMA delivered a statement at the 52 Regular Session of the Human Rights Council (HRC) for the Interactive Dialogue with the Human Rights Commissioner on the report on Access to COVID-19 Vaccines.

Position paper 1 Mar 2023

Fee system for regional joint assessment procedures in Africa

This joint position paper covers the perspective from industry on the proposed fee system for regional joint assessment procedures in Africa.

Statement 28 Feb 2023

Industry statement at fourth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response

On 28 February, IFPMA delivered a statement at the fourth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response held from 27 February - 3 March 2023.

Statement 24 Feb 2023

Industry statement on the earthquakes in Türkiye and Syria

In the wake of the devastating earthquakes in Türkiye and Syria, a number of our member companies are working to ensure supply chains function and get vital medicines to existing patients, as well as medical supplies and financial donations to those affected by the earthquakes. Industry will also continue to work with partners and authorities to provide further support where possible.

Statement 21 Feb 2023

Second meeting of the Working Group on Amendments to the International Health Regulations (2005) (WGIHR)

On 21 February, IFPMA delivered a statement at the second meeting of the Working Group on amendments to the International Health Regulations (2005) (WGIHR) held from 20-24 February 2023.

Expert insight 16 Feb 2023

Five priorities for future pandemic preparedness and response

As the global architecture for pandemic preparedness and response is discussed, IFPMA shares practical solutions and recommends focusing on five priorities.

Statement 15 Feb 2023

WHO briefing for relevant stakeholders on the Zero Draft WHO CA+

On 15 February, IFPMA attended a briefing for relevant stakeholders on the Zero Draft WHO CA+ in Geneva and delivered a statement on industry’s preliminary comments.

Position paper 15 Feb 2023

Pharmacy-mediated substitution for biosimilars

This position paper from IFPMA addresses substitution relating to biosimilars and their reference products at the retail pharmacy level. While this practice has been in place in many countries for generics, for biosimilars, the practice is only emerging.

Position paper 15 Feb 2023

Convergence and reliance approaches for advanced therapy medicinal products

Cell, tissue and gene therapies offer significant potential to treat diseases with high unmet medical needs, and consist of human cell and tissue products for medical use and advanced therapy medicinal products (ATMPs). IFPMA shares points to consider when promoting regulatory convergence and reliance approaches for ATMPs.

Expert insight 14 Feb 2023

Five Priorities to Global Pandemic Preparedness

As the global architecture for pandemic preparedness and response is discussed, IFPMA shares practical solutions and recommends focusing on five priorities.

Press release 13 Feb 2023

Pharma recommends five priorities for future pandemic preparedness and response

As the global architecture for pandemic preparedness and response is discussed, IFPMA shares practical solutions and recommends focussing on five priorities.